<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02039518</url>
  </required_header>
  <id_info>
    <org_study_id>WXH-gemcitabine-SCLC</org_study_id>
    <nct_id>NCT02039518</nct_id>
  </id_info>
  <brief_title>Study of Gemcitabine Maintenance Treatment in Patients With Extensive SCLC Patients</brief_title>
  <official_title>Randomized Controlled Trial of Gemcitabine Maintenance Treatment in Patients With Extensive SCLC Patients Receiving Etoposide Combined With Platinum Based First-line Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to Evaluate and compare safety and efficacy of Gemcitabine
      Maintenance Treatment in Patients With Extensive SCLC Patients Receiving Etoposide Combined
      With Platinum Based First-line Chemotherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      from the first cycle of treatment (day one) to two month after the last cycle
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>from the first cycle of treatment (day one) to two month after the last cycle</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gemcitabine 1000mg/m2，d1，d8，Q3W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>observation group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>observation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>gemcitabine 1000mg/m2，d1，d8，Q3W</description>
    <arm_group_label>gemcitabine</arm_group_label>
    <other_name>gemcitabine 1000mg/m2，d1，d8，Q3W</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>observation group</intervention_name>
    <description>observation group</description>
    <arm_group_label>observation group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥18 years

          2. PS=0,1,2

          3. Patients who were diagnosed by the histologic, cytologic diagnosis of extensive small
             cell lung cancer

          4. Patients received Etoposide combined with platinum based first-line chemotherapy 6
             cycles and there is evidence show the patent is PR/CR/SD

          5. Expected lifetime&gt;12 weeks

          6. Signed written informed consent

        Exclusion Criteria:

        Small cell lung cancer non small cell hybrid Women during pregnancy or lactation previously
        treated with two or more than two kinds of treatment Any non remission of &gt;CTCAE caused
        tumor treatment past grade 2 toxicity Ccr&lt;30 ml/min (calculated by Cockcroft-Gault formula)
        hepatic insufficiency：

          1. Tbil&gt; 1.5×ULN

          2. ALT and AST &gt; 2.5×ULN (Patients with liver metastasis&gt;5×ULN) Alkaline phosphatase＞2.5
             ×ULN(Patients with liver metastasis&gt;5×ULN)

          3. Severe symptomatic heart disease

          4. Symptomatic brain metastases

          5. In the last 5 years have been or are suffering from other histological types of
             malignant tumor

          6. There are serious or uncontrolled systemic diseases

          7. During the study period planned radiotherapy on target lesion

          8. During the study period, plans to use other antineoplastic therapy

          9. Clinical study on treatment of 30 days beginning period prior to participate in any
             study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>WU X HUA, DOCTOR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wu X Hua, doctor</last_name>
    <phone>13482888167</phone>
    <email>xhwu2011@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wu X hua, doctor</last_name>
      <phone>13482888167</phone>
      <email>xhwu2011@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2013</study_first_submitted>
  <study_first_submitted_qc>January 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2014</study_first_posted>
  <last_update_submitted>January 15, 2014</last_update_submitted>
  <last_update_submitted_qc>January 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xianghua Wu</investigator_full_name>
    <investigator_title>Associate Chief Physician</investigator_title>
  </responsible_party>
  <keyword>Progression free Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

